Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors and subsidiary of Beyond Air, Inc. (NASDAQ: ...

gClinical Research Design Division, Clinical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, 510120, China hDepartment of Ophthalmology, Wuhan Wuchang ...

For those that do survive the virus, it is noted that they often have long term neurological sequelae, including the development of epilepsy, personality changes and even the potential for a ...

Heeding the recommendation of an independent data monitoring committee, Calcimedica Inc. said it is discontinuing the phase II study testing calcium release-activated calcium channel inhibitor Auxora ...

CalciMedica has terminated a Phase II study on its lead asset, Auxora (zegocractin), in acute kidney injury (AKI) with ...

Laura Dern made one final vow to her mother, Diane Ladd, before her death from lung disease. “I made a promise to my mom that ...

CalciMedica shares fell after the company stopped its Phase 2 KOURAGE trial for Auxora due to safety concerns.

CalciMedica shares were 82% lower, at 91 cents, after the company said it was discontinuing its Phase 2 clinical trial evaluating Auxora in patients with Stage 2 or Stage 3 acute kidney injury with ...

CalciMedica had been evaluating the therapy, called Auxora, in the Kourage trial of patients with stage 2 or 3 AKI with ...

CalciMedica Inc. ("CalciMedica" or the "Company") , a clinical-stage biopharmaceutical company developing novel calcium ...

Investing.com -- CalciMedica Inc. (NASDAQ:CALC) stock plunged 80% Wednesday after the company announced it was discontinuing its Phase 2 KOURAGE clinical trial for acute kidney injury following safety ...